FUSEN PHARM Gains NMPA Marketing Approval for Glucosamine Sulfate Capsule

Bulletin Express

Apr 17

Fusen Pharmaceutical Company Limited (FUSEN PHARM) announced that its wholly owned unit, Henan Fusen Pharmaceutical, has received National Medical Products Administration approval to market “Glucosamine Sulfate Capsule” (trademark: Shuhuitong) for the treatment of primary and secondary osteoarthritis.

The capsule contains natural amino monosaccharides vital to articular cartilage matrix synthesis. By repairing cartilage, alleviating pain and improving joint function, the therapy targets the long-term management needs of osteoarthritis—a degenerative condition linked to aging, body weight and joint strain.

Classified as a Class B medicine in the National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug Catalog (2025 Edition), Glucosamine Sulfate Capsules generated industry-wide sales exceeding RMB850.00 million in 2024, reflecting year-on-year growth of 25.28%. Sales for the first three quarters of 2025 rose 26.84% year on year, according to Menet data.

Management highlighted that China’s aging demographic and rising prevalence of joint disorders underpin sustained demand growth. The new approval broadens FUSEN PHARM’s product pipeline and reinforces the group’s positioning in the osteoarthritis therapeutic segment, offering additional treatment options to patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/news/1140687513"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1140687513\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1140687513?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-17 22:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140687513","market":"us","top_or_hot":-1,"title":"FUSEN PHARM Gains NMPA Marketing Approval for Glucosamine Sulfate Capsule","media":"Bulletin Express","content":"<p>Fusen Pharmaceutical Company Limited (FUSEN PHARM) announced that its wholly owned unit, Henan Fusen Pharmaceutical, has received National Medical Products Administration approval to market “Glucosamine Sulfate Capsule” (trademark: Shuhuitong) for the treatment of primary and secondary osteoarthritis.</p>\n<p>The capsule contains natural amino monosaccharides vital to articular cartilage matrix synthesis. By repairing cartilage, alleviating pain and improving joint function, the therapy targets the long-term management needs of osteoarthritis—a degenerative condition linked to aging, body weight and joint strain.</p>\n<p>Classified as a Class B medicine in the National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug Catalog (2025 Edition), Glucosamine Sulfate Capsules generated industry-wide sales exceeding RMB850.00 million in 2024, reflecting year-on-year growth of 25.28%. Sales for the first three quarters of 2025 rose 26.84% year on year, according to Menet data.</p>\n<p>Management highlighted that China’s aging demographic and rising prevalence of joint disorders underpin sustained demand growth. The new approval broadens FUSEN PHARM’s product pipeline and reinforces the group’s positioning in the osteoarthritis therapeutic segment, offering additional treatment options to patients.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FUSEN PHARM Gains NMPA Marketing Approval for Glucosamine Sulfate Capsule</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFUSEN PHARM Gains NMPA Marketing Approval for Glucosamine Sulfate Capsule\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-17 22:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fusen Pharmaceutical Company Limited (FUSEN PHARM) announced that its wholly owned unit, Henan Fusen Pharmaceutical, has received National Medical Products Administration approval to market “Glucosamine Sulfate Capsule” (trademark: Shuhuitong) for the treatment of primary and secondary osteoarthritis.</p>\n<p>The capsule contains natural amino monosaccharides vital to articular cartilage matrix synthesis. By repairing cartilage, alleviating pain and improving joint function, the therapy targets the long-term management needs of osteoarthritis—a degenerative condition linked to aging, body weight and joint strain.</p>\n<p>Classified as a Class B medicine in the National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug Catalog (2025 Edition), Glucosamine Sulfate Capsules generated industry-wide sales exceeding RMB850.00 million in 2024, reflecting year-on-year growth of 25.28%. Sales for the first three quarters of 2025 rose 26.84% year on year, according to Menet data.</p>\n<p>Management highlighted that China’s aging demographic and rising prevalence of joint disorders underpin sustained demand growth. The new approval broadens FUSEN PHARM’s product pipeline and reinforces the group’s positioning in the osteoarthritis therapeutic segment, offering additional treatment options to patients.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01652","symbol_name":"福森药业","start_time":0,"source_url":"","article_id":"1140687513","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140687513","pubTimestamp":1776435867,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Fusen Pharmaceutical Company Limited (FUSEN PHARM) announced that its wholly owned unit, Henan Fusen Pharmaceutical, has received National Medical Products Administration approval to market...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01652":"福森药业"},"translate_title":"福森药业硫酸氨基葡萄糖胶囊获NMPA上市批件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01652":1},"content_text":"Fusen Pharmaceutical Company Limited (FUSEN PHARM) announced that its wholly owned unit, Henan Fusen Pharmaceutical, has received National Medical Products Administration approval to market “Glucosamine Sulfate Capsule” (trademark: Shuhuitong) for the treatment of primary and secondary osteoarthritis.\nThe capsule contains natural amino monosaccharides vital to articular cartilage matrix synthesis. By repairing cartilage, alleviating pain and improving joint function, the therapy targets the long-term management needs of osteoarthritis—a degenerative condition linked to aging, body weight and joint strain.\nClassified as a Class B medicine in the National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug Catalog (2025 Edition), Glucosamine Sulfate Capsules generated industry-wide sales exceeding RMB850.00 million in 2024, reflecting year-on-year growth of 25.28%. Sales for the first three quarters of 2025 rose 26.84% year on year, according to Menet data.\nManagement highlighted that China’s aging demographic and rising prevalence of joint disorders underpin sustained demand growth. The new approval broadens FUSEN PHARM’s product pipeline and reinforces the group’s positioning in the osteoarthritis therapeutic segment, offering additional treatment options to patients.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}